1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,540 | 2,840 | 23:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 14:06 | Aclarion, Inc.: Aclarion Receives Pinnacle Award for AI Innovation | 1 | GlobeNewswire (USA) | ||
| Mi | Aclarion establishes agreement with Weill Cornell Medicine | 1 | Investing.com | ||
| 07.04. | Aclarion, Inc.: Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video | 1 | GlobeNewswire (USA) | ||
| 24.03. | Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. | 229 | ACCESS Newswire | Stock has declined 99% since its IPOBelieves Neal has repeatedly failed to fulfill his fiduciary responsibilitySince 2021 Neal has received $240,000 Board compensationAccepted 20% pay increase in 2025... ► Artikel lesen | |
| 19.03. | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Aclarion, Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 19.03. | Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan | 3 | GlobeNewswire (USA) | ||
| 19.03. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts | 292 | GlobeNewswire (Europe) | Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong... ► Artikel lesen | |
| 12.03. | Aclarion, Inc.: Aclarion CEO Brent Ness to Attend LSI USA 2026 | 1 | GlobeNewswire (USA) | ||
| 05.02. | Aclarion, Inc.: Aclarion Publishes 2026 Shareholder Letter from the Chairman | 214 | GlobeNewswire (Europe) | Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026... ► Artikel lesen | |
| 03.02. | Aclarion partners with Source Healthcare to expand Nociscan availability | 1 | Investing.com | ||
| 03.02. | Aclarion erweitert Verfügbarkeit von Nociscan durch Partnerschaft mit Source Healthcare | 2 | Investing.com Deutsch | ||
| 03.02. | Aclarion, Inc.: Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation | 1 | GlobeNewswire (USA) | ||
| 13.01. | Aclarion raises $10.4 million to fund chronic back pain technology | 3 | Investing.com | ||
| 13.01. | Aclarion schließt Finanzierung über 10,4 Millionen US-Dollar für Technologie gegen Rückenschmerzen ab | 8 | Investing.com Deutsch | ||
| 13.01. | Aclarion, Inc.: Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 | 457 | GlobeNewswire (Europe) | BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 09.01. | Aclarion, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Aclarion Stock Climbs 50% After Strong 2025 Results And 2026 Outlook | 9 | RTTNews | ||
| 08.01. | Aclarion-Aktie steigt sprunghaft an: Scan-Volumen von Nociscan im 4. Quartal um 114 % gewachsen | 11 | Investing.com Deutsch | ||
| 08.01. | Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars | 9 | Benzinga.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 267,60 | +0,53 % | UnitedHealth-Aktie: Auftakt zu einem großen Comeback? | Seit über zwei Monaten dümpelt die UnitedHealth-Aktie in einem Seitwärtstrend vor sich hin. Doch am Dienstagmorgen gelingt der größten Krankenversicherung der USA mit einem Kursplus von über +8% der... ► Artikel lesen | |
| INTUITIVE SURGICAL | 397,75 | +1,93 % | Future Market Insights: Global Lung Cancer Surgery Market | Rise at 5.9% CAGR | Medtronic, Ethicon, Intuitive Surgical Drive Precision Oncology Advancements | For healthcare providers, surgical centers, and medical device manufacturers, lung cancer surgery remains a cornerstone of oncology care-particularly for early-stage diagnosis-where precision, patient... ► Artikel lesen | |
| THERMO FISHER | 448,20 | +2,49 % | Thermo Fisher Scientific, HealthVerity Partner to Expand Real-World Data Capabilities | ||
| ROKU | 90,50 | +2,98 % | Research: Roku, Amazon TV OS gaining influence in US homes | ||
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update | SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 31,800 | -0,13 % | What Offers Centene Corporation (CNC) an Attractive Growth Outlook? | ||
| QUIDELORTHO | 14,720 | +8,92 % | UBS cuts Quidel stock price target on weaker respiratory season | ||
| VERU | 2,420 | +1,26 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 2,250 | +7,66 % | Tempest Therapeutics: Tempest Reports Year End 2025 Financial Results and Provides Business Update | Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing... ► Artikel lesen | |
| NANO-X IMAGING | 2,470 | +4,00 % | NANO-X IMAGING LTD: Nanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas | Fourth distribution agreement of 2026 strengthens Nanox's U.S. commercial momentum
PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (NASDAQ NNOX), a leader in innovative... ► Artikel lesen | |
| FULGENT GENETICS | 13,500 | +3,85 % | Fulgent Genetics completes $56.9M pathology lab acquisitions | ||
| LANTHEUS | 70,30 | +1,15 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection | New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,560 | -2,36 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results | Lead program VMT-a-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported... ► Artikel lesen | |
| OMNICELL | 30,200 | +1,34 % | Benchmark reiterates Omnicell stock rating on product cycle outlook |
ACLARION INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -1,56 % bei einem Aktienkurs von 2,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.